Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations.
Fenge LiLigang DengKyle R JacksonAmjad H TalukderArjun S KatailihaSherille D BradleyQingwei ZouCaixia ChenChong HuoYulun ChiuMatthew StairWeihong FengAleksander BagaevNikita KotlovViktor SvekolkinRavshan AtaullakhanovNatalia MiheechevaFelix FrenkelYaling WangMinying ZhangDavid HawkeLing HanShuo ZhouYan ZhangZhenglu WangWilliam K DeckerHeather M SonnemannJason RoszikMarie-Andree ForgetMichael A DaviesChantale BernatchezCassian YeeRoland BassettPatrick HwuXueming DuGregory LizéePublished in: Journal for immunotherapy of cancer (2022)
These results show that personalized NeoAg vaccination is feasible and safe for advanced-stage NSCLC patients. The clinical and immune responses observed following PPV suggest that EGFR mutations constitute shared, immunogenic neoantigens with promising immunotherapeutic potential for large subsets of NSCLC patients. Furthermore, PPV with concurrent EGFR inhibitor therapy was well tolerated and may have contributed to the induction of PPV-induced T cell responses.
Keyphrases
- small cell lung cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- epidermal growth factor receptor
- tyrosine kinase
- peritoneal dialysis
- prognostic factors
- advanced non small cell lung cancer
- peripheral blood
- patient reported outcomes
- toll like receptor
- dendritic cells
- rectal cancer
- brain metastases
- smoking cessation